logo
Kyivstar Group files registration statement on Form F-4

Kyivstar Group files registration statement on Form F-4

Kyivstar Group Ltd., Ukraine's leading digital operator and a subsidiary of Veon Ltd. (VEON) announced the public filing of its Registration Statement on Form F-4 with the SEC. This filing represents a milestone in Kyivstar Group's plans to be listed on the Nasdaq Stock Market following the anticipated completion of a business combination with Cohen Circle Acquisition Corp. I (CCIR) that was announced on March 18, 2025.
Confident Investing Starts Here:

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aura Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
Aura Announces Public Filing of Registration Statement for Proposed U.S. Public Offering

Yahoo

time8 hours ago

  • Yahoo

Aura Announces Public Filing of Registration Statement for Proposed U.S. Public Offering

ROAD TOWN, British Virgin Islands, June 06, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) ('Aura' or the 'Company') announces that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed public offering of its securities in the United States. The proposed public offering includes the registration and listing of our common shares in the United States. The public offering is expected to commence after the SEC completes its review processes, subject to market and other conditions. The number of common shares to be sold and the price range for the proposed offering have not yet been determined. There will be no pre-emptive right for our shareholders and our Brazilian Depositary Receipts holders in connection with the public offering. Aura has applied to list its common shares on the Nasdaq Global Select Market under the symbol 'AUGO.' The U.S. listing is part of Aura's strategy to unlock value for our shareholders, improve stock liquidity and consolidate the liquidity in the U.S. equity market. BofA Securities and Goldman Sachs & Co. LLC are acting as Global Coordinators, BTG Pactual and Itaú BBA are acting as Joint Bookrunners and Bradesco BBI, National Bank of Canada Financial Markets, RBC Capital Markets and Scotiabank are acting as Co-Managers of the offering. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained, when available, from BofA Securities, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department. A registration statement relating to this offering has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering will not be carried out by any means that would constitute a public offering in Brazil under Law No. 6,385, dated December 7, 1976, as amended, and under Brazilian Securities Commission ('CVM') Resolution (Resolução) No. 160, dated July 13, 2022, as amended ('CVM Resolution 160'). The offering has not been and will not be registered with the CVM in Brazil. The common shares may not be offered or sold in Brazil except in circumstances which do not constitute a public offering for distribution under Brazilian securities laws and regulations. Caution Regarding Forward-Looking Information and Statements This press release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws and/or "forward-looking statements" within the meaning of applicable United States securities laws (collectively, "forward-looking statements"). Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: statements relating to the public offering of the Company's common shares; the expected timing of the public offering; the registration and listing of the Company's common shares in the United States; the registration statement becoming effective; the SEC's review process; the sizing and pricing of the offering; the means by which the offering will be made; and the Company's business strategies. Often, but not always, forward-looking statements may be identified by the use of words such as "expects", "anticipates", "plans", "projects", "estimates", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, the following estimates and assumptions: the Company carrying out its public offering; the Company successfully completing the SEC review process; obtaining requisite regulatory approvals; and general business, economic and market conditions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Important factors that may cause actual results to vary, include, without limitation, that the Company may not carry out its public offering or complete the SEC review process. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement or forward-looking information, except in accordance with applicable securities laws. CONTACT: Investor Relations ri@

VS MEDIA Announces Closing of an Additional $1.1 Million Following its Recent Public Offering of Ordinary Shares, Bringing the Total Gross Proceeds to Approximately $9.2 Million
VS MEDIA Announces Closing of an Additional $1.1 Million Following its Recent Public Offering of Ordinary Shares, Bringing the Total Gross Proceeds to Approximately $9.2 Million

Yahoo

time16 hours ago

  • Yahoo

VS MEDIA Announces Closing of an Additional $1.1 Million Following its Recent Public Offering of Ordinary Shares, Bringing the Total Gross Proceeds to Approximately $9.2 Million

Hong Kong, June 06, 2025 (GLOBE NEWSWIRE) -- VS MEDIA Holdings Limited (Nasdaq: VSME), a leading digital media and social commerce company in the global Creator Economy, today announced the subsequent closing of its public offering of 4,774,235 ordinary shares at a public offering price of $0.229 per ordinary share. This additional closing generated additional gross proceeds of $1,093,300, supplementing the recent public offering announced on May 30, 2025. As a result, the total number of issued ordinary shares has increased to 40,070,298, all at a public offering price of $0.229 per ordinary share. Gross proceeds of the offering from two closings were $9,176,100. Net proceeds of the offering from two closings, after deducting placement agent fees and other offering expenses of $774,351, were $8,401,749. Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this additional closing. The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333-286658) (the 'Registration Statement'), which was declared effective by the Securities and Exchange Commission (the 'SEC') on May 6, 2025. The offering was being made only by means of a prospectus, which is a part of the Registration Statement. A final prospectus relating to the offering has been filed with the SEC. Copies may be obtained from Joseph Gunnar & Co., LLC, Attn: Syndicate Department, 40 Wall Street, Suite 3004, New York, NY 10005, by calling (212) 440-9600. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About VS Media: VS Media Holdings Limited (NASDAQ:VSME) manages a network of leading digital creators across Asia Pacific that powers content-driven social commerce and offers local and effective marketing services to brands. Founded in 2013, VSME partners with over 1,500 creators and over 1,000 brands to promote and merchandise their products and services. The Company is currently growing internationally across Hong Kong, China, Taiwan, Singapore, and beyond. For more information, visit Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Investors can find many (but not all) of these statements by the use of words such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'likely to' or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Contact Information: Crescendo Communications, LLC Tel: +1 212-671-1020 Email: vsme@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AI helped design an innovative new cancer treatment plan
AI helped design an innovative new cancer treatment plan

Yahoo

timea day ago

  • Yahoo

AI helped design an innovative new cancer treatment plan

If you purchase an independently reviewed product or service through a link on our website, BGR may receive an affiliate commission. Researchers may have come up with an interesting new treatment for cancer by talking to AI. According to a paper published this month, a research team led by the University of Cambridge turned to an 'AI scientist' powered by GPT-4 to help create a new AI-designed cancer treatment plan. The kicker? It only uses widely available drugs that have nothing to do with treating cancer. The researchers started by taking all of the data they had regarding popular drugs used to treat high cholesterol and alcohol dependence to look for hidden patterns that could point toward new cancer drug options. They prompted GPT-4 to identify combinations of the drugs that could possibly have a significant impact on breast cancer cells. Today's Top Deals Best deals: Tech, laptops, TVs, and more sales Best Ring Video Doorbell deals Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98 The result is a new AI-designed cancer treatment plan that avoids standard cancer drugs and relies on drugs that will not target non-cancerous cells. The drugs that the AI was prompted to look for were also meant to be widely available, affordable, and already approved by regulators. Considering how many different types of cancer treatment options we've seen in recent years, this approach makes a lot of sense. It also opened some new doors, according to the researcher's findings, which are published in the Journal of Royal Society Interface. We've seen a huge increase in researchers and doctors turning to AI to try to come up with new treatment options for old problems, including an AI that can identify autism. So it isn't that surprising to see researchers once more turning to AI to help speed up scientific progress. It seems to have worked, too. According to the findings, the researchers tested the combinations suggested by the GPT-4 'scientist' and found that three of the 12 combinations worked better than current breast cancer drugs. They then fed that information back to the AI, which created four more combinations, three of which also showed a lot of promise. Of course, relying wholly on AI-designed cancer treatment plans isn't something doctors are likely to do immediately. More trials and research are needed to fully test the efficiency of these drug combinations. Testing will also need to be done to ensure there aren't any adverse side effects from combining these drugs over extended periods of time. But for those fighting cancer right now, research like this is promising and could one day help scientists find even better treatment options. And even if the AI hallucinates, the information it gives may spark a new idea that scientists hadn't thought of before. AI will never replace doctors, no matter how hard Google and others push for a future involving AI doctors. But by relying on AI to speed up research, scientists can potentially unlock new options they might not otherwise find for decades to come. More Top Deals Amazon gift card deals, offers & coupons 2025: Get $2,000+ free See the

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store